Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis

Next Previous
Trial Profile

A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Ciclosporin; Corticosteroids; Corticosteroids; Etretinate; Methotrexate
  • Indications Pustular psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors AbbVie

Most Recent Events

  • 23 Mar 2018 Results published in the Media Release
  • 23 Mar 2018 According to an AbbVie media release, based on the results of this trial the company has received additional approval for a new indication of HUMIRA in the treatment of patients who have had an inadequate response to conventional therapy for pustular psoriasis.
  • 21 Jul 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top